Success Metrics

Clinical Success Rate
90.0%

Based on 27 completed trials

Completion Rate
90%(27/30)
Active Trials
5(12%)
Results Posted
22%(6 trials)
Terminated
3(7%)

Phase Distribution

Ph phase_1
13
31%
Ph phase_2
2
5%
Ph phase_3
2
5%
Ph not_applicable
7
17%
Ph phase_4
10
24%

Phase Distribution

13

Early Stage

2

Mid Stage

12

Late Stage

Phase Distribution34 total trials
Phase 1Safety & dosage
13(38.2%)
Phase 2Efficacy & side effects
2(5.9%)
Phase 3Large-scale testing
2(5.9%)
Phase 4Post-market surveillance
10(29.4%)
N/ANon-phased studies
7(20.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

79.4%

27 of 34 finished

Non-Completion Rate

20.6%

7 ended early

Currently Active

5

trials recruiting

Total Trials

42

all time

Status Distribution
Active(8)
Completed(27)
Terminated(7)

Detailed Status

Completed27
Recruiting4
Withdrawn4
Not yet recruiting3
Terminated3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
42
Active
5
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 113 (38.2%)
Phase 22 (5.9%)
Phase 32 (5.9%)
Phase 410 (29.4%)
N/A7 (20.6%)

Trials by Status

active_not_recruiting12%
completed2764%
not_yet_recruiting37%
terminated37%
recruiting410%
withdrawn410%

Recent Activity

Clinical Trials (42)

Showing 20 of 42 trialsScroll for more
NCT07809919Phase 1

A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects

Completed
NCT05580250Phase 1

A Study of LY3526318 in Healthy Male Japanese Participants

Withdrawn
NCT07643467Phase 4

Fluorescent Probe for Assessment of Renal Elimination

Not Yet Recruiting
NCT05065073Phase 4

Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography

Completed
NCT07349797Not Applicable

MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure

Recruiting
NCT04113109Phase 4

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

Completed
NCT03997370Phase 1

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Active Not Recruiting
NCT06709521Phase 4

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

Completed
NCT07339722Phase 1

A Study of LY4515100 in Healthy Participants

Recruiting
NCT02961478Phase 3

Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure

Completed
NCT04649229Phase 4

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

Completed
NCT07174440Not Applicable

Contrast and Anesthetic Level With Lumbar Erector Spinae Plan (ESP) Block

Recruiting
NCT04776486Not Applicable

Iohexol Clearance in Critically Ill Patients With Augmented Renal Creatinine Clearance

Completed
NCT07391787

Low-acid Contrast Media for Preventing Post ERCP Pancreatitis

Completed
NCT02050269Phase 3

Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study

Completed
NCT04582500

Virtual Colonoscopy Using Omnipaque as a Contrast Agent

Completed
NCT05442463

Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans

Recruiting
NCT05105009Phase 1

Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function

Completed
NCT05136963Phase 1

Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance

Not Yet Recruiting
NCT06259422Not Applicable

Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
42